GlassScriptPhysician profile
George Kanes
NPI 1124012554
$4,528.09
in general payments reported to CMS, 2019-2025
35 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $370 · 2021: $470 · 2022: $497 · 2023: $673 · 2024: $1,122 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,890.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.15 | 2020-2025 | |
| Novo Nordisk INC | $487.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $424.12 | 2020-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $218.20 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Allergan, INC. | $185.53 | 2019-2020 | |
| Glaxosmithkline, LLC. | $146.40 | 2019-2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $145.09 | 2023-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $144.47 | 2019-2023 | Livalo, Seglentis |
| Pfizer INC. | $132.30 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $131.04 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $126.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.36 | 2019-2023 | Trintellix |
| Exact Sciences Corporation | $103.65 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $83.05 | 2019 | |
| Biofire Diagnostics, LLC | $80.67 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $66.46 | 2023-2024 | Rexulti |
| Currax Pharmaceuticals LLC | $65.10 | 2020-2021 | |
| Abbott Laboratories | $61.25 | 2021-2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $49.97 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $48.03 | 2023-2025 | Lagevrio, Belsomra |
| Eisai INC. | $44.58 | 2021 | |
| Axsome Therapeutics, INC. | $43.81 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.91 | 2021-2025 | Xifaxan |
| Neos Therapeutics, LP | $39.96 | 2023 | Adzenys Xr-Odt |
| Shire North American Group INC | $38.84 | 2019 | |
| Nevro Corp. | $32.37 | 2024 | Senza |
| Boston Scientific Corporation | $26.14 | 2025 | General - Pain Management |
| Inspire Medical Systems, INC. | $25.61 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $25.27 | 2025 | Nuzyra |
| Medtronic, INC. | $24.44 | 2024 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $21.41 | 2025 | |
| Supernus Pharmaceuticals, INC. | $21.41 | 2025 | Qelbree |
| Sanofi Pasteur INC. | $20.83 | 2025 | |
| Horizon Therapeutics Plc | $19.63 | 2023 | Krystexxa |
| Linus Health, INC. | $13.88 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Kanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.